06022079

35/532

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0076
Expires: April 30, 2008
Estimated average burden hours per response.. . 1

SEC MAIL PROCESSING RECEIVED MAR 2 2 2006 WASH., D.C. 209 SECTION

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

SEC USE ONLY		
Prefix		Serial
DATE RECEIVED		

Name of Offering ([X] check if this is an amendment and name has changed, and indicate change.) **Stem Cell Innovations, Inc. (f/k/a Interferon Sciences, Inc.)**

Filing Under (Check box(es) that apply): [ ] Rule 504 [ ] Rule 505 [X] Rule 506 [ ] Section 4(6) [ ] ULOE

Type of Filing: [ ] New Filing [X] Amendment

PROCESSED
MAR 2 9 2006
THOMSON FINANCIAL

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer ([X] check if this is an amendment and name has changed, and indicate change.)
Stem Cell Innovations, Inc. (f/k/a Interferon Sciences, Inc.)

Address of Executive Offices (Number and Street, City, State, Zip Code)
Telephone Number (Including Area Code)
1812 Front Street, Scotch Plains, NJ 07076 (908) 663-2150

Address of Principal Business Operations (Number and Street, City, State, Zip Code)
Telephone Number (Including Area Code)
(if different from Executive Offices)

Brief Description of Business
Holding Company

Type of Business Organization

[X] corporation [ ] limited partnership, already formed [ ] other (please specify):

[ ] business trust [ ] limited partnership, to be formed

	Month	Year		
Actual or Estimated Date of Incorporation or Organization:	[0]1]	[8]4]	[ ] Actual	[X] Estimated

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction) [D] [E]

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix in the notice constitutes a part of this notice and must be completed.

A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and

- Each general and managing partner of partnership issuers.

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [X] Executive Officer [X] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Ronel, Samuel H.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [X] Executive Officer [X] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Gordon Lawrence M.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [X] Executive Officer [ ] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Schutzbank, Stanley G.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [ ] Executive Officer [X] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Glashow, Sheldon L.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

Check Box(es) that Apply: [ ] Promoter [X] Beneficial Owner [ ] Executive Officer [ ] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Chassman, Margie**

Business or Residence Address (Number and Street, City, State, Zip Code)
445 West 23rd Street, New York, NY 10011

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [X] Executive Officer [ ] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Anderson, Donald W.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

Check Box(es) that Apply: [ ] Promoter [ ] Beneficial Owner [X] Executive Officer [ ] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual) **Kelly, James H.**

Business or Residence Address (Number and Street, City, State, Zip Code)
c/o Stem Cell Innovations, Inc., 1812 Front Street, Scotch Plains, NJ 07076

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

B. INFORMATION ABOUT OFFERING

	Yes	No
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?.....	[ ]	[X]

Answer also in Appendix, Column 2, if filing under ULOE.

2. What is the minimum investment that will be accepted from any individual?..... **$ N/A**

	Yes	No
3. Does the offering permit joint ownership of a single unit?.....	[X]	[ ]

4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.

Full Name (Last name first, if individual)
Broadband Capital Management

Business or Residence Address (Number and Street, City, State, Zip Code)
805 3rd Ave., New York, NY 10022

Name of Associated Broker or Dealer
Broadband Capital Management

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers
(Check "All States" or check individual States) ..... [ ] All States

[AL]	[AK]	[AZ]	[AR]	[~~CA~~]	[CO]	[CT]	[DE]	[DC]	[~~FL~~]	[~~GA~~]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[~~MD~~]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[~~NY~~]	[~~NC~~]	[ND]	[OH]	[OK]	[OR]	[~~PA~~]
[RI]	[SC]	[SD]	[~~TN~~]	[~~TX~~]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

Full Name (Last name first, if individual)
Strategic Biotech Advisors

Business or Residence Address (Number and Street, City, State, Zip Code)
7234 Industry Dr., North Charleston, SC 29418

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) ..... [ ] All States

[AL]	[AK]	[AZ]	[AR]	[~~CA~~]	[CO]	[CT]	[DE]	[DC]	[~~FL~~]	[~~GA~~]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[~~MD~~]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[~~NY~~]	[~~NC~~]	[ND]	[OH]	[OK]	[OR]	[~~PA~~]
[RI]	[SC]	[SD]	[~~TN~~]	[~~TX~~]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) ..... [ ] All States

[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box [**X**] and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

Type of Security	Aggregate Offering Price	Amount Already Sold
Debt	$ 2,935,000.00	$ 0.00
Equity	$ 3,065,000.00	$ 0.00
[ ] Common [**X**] Preferred		
Convertible Securities (including warrants)	$ 11,400,000.00	$ 0.00
Partnership Interests	$_____	$_____
Other (Specify _____)	$_____	$_____
Total	$ 17,400,000.00	$ 0.00

Answer also in Appendix, Column 3, if filing under ULOE.

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or

"zero."

	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors	36	$ 0.00
Non-accredited Investors	0	$ 0.00
Total (for filings under Rule 504 only)	$ _____	$ _____

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C-Question 1.

Type of offering	Type of Security	Dollar Amount Sold
Rule 505	_____	$ _____
Regulation A	_____	$ _____
Rule 504	_____	$ _____
Total	_____	$ _____

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

Transfer Agent's Fees	[ ] $ _____
Printing and Engraving Costs	[ ] $ _____
Legal Fees	[ ] $ 115,000.00
Accounting Fees	[ ] $ 40,000.00
Engineering Fees	[ ] $ _____
Sales Commissions (specify finders' fees separately)	[ ] $ _____
Other Expenses (identify) **Finder's Fee**	[ ] $ 193,175.00
Structuring Fee	[ ] $ 50,000.00
Total	[ ] $ 398,175.00

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." ..... $ 17,001,825.00

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth

proceeds to the issuer set forth in response to Part C - Question 4.b above.

	Payments to Officers, Directors, & Affiliates	Payments To Others
Salaries and fees	[ ] $_____	[ ] $_____
Purchase of real estate	[ ] $_____	[ ] $_____
Purchase, rental or leasing and installation of machinery and equipment	[ ] $_____	[ ] $_____
Construction or leasing of plant buildings and facilities	[ ] $_____	[ ] $_____
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	[X] $11,001,825	[X] $_____
Repayment of indebtedness	[ ] $_____	[ ] $_____
Working capital	[ ] $_____	[ ] $_____
Other (specify): Restructuring investor's investment in the business to be acquired	[ ] $_____	[X] $6,000,000
	[ ] $_____	[ ] $_____
Column Totals	[X] $11,001,825	[X] $6,000,000
Total Payments Listed (column totals added)	[X] $17,001,825	

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type)	Signature	Date
Stem Cell Innovations, Inc.	James H. Kelly	February 22, 2006
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
James H. Kelly	President and CEO	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

E. STATE SIGNATURE

1. Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule? Yes [ ] No [X]

See Appendix, Column 5, for state response.

2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.

3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.

4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)	Signature	Date
Stem Cell Innovations, Inc.	James H Kelly	2/22/06
Name of Signer (Print or Type)	Title (Print or Type)	
James H. Kelly	President and CEO	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	2		3	4				5	
	Intend to sell to non-accredited investors in State (Part B-Item 1)		Type of security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL									

AK									
AZ									
AR									
CA		X	**Convertible Securities** $876,923.08	3	$0.00	0	$0.00		X
CO									
CT									
DE									
DC									
FL		X	**Convertible Securities** $292,307.69	1	$0.00	0	$0.00		X
GA		X	**Convertible Securities** $3,800,000.00	13	$0.00	0	$0.00		X
HI									
ID									
IL									
IN									
IA									
KS									
KY									
LA									
ME									
MD		X	**Convertible Securities** $292,307.69	1	$0.00	0	$0.00		X
MA									
MI									
MN									
MS									
MO									
MT									
NE									
NV									
NH									
NJ									
NM									
NY		X	**Convertible**	5	$0.00	0	$0.00		X

			Securities $7,410,000.000						
NC		X	**Convertible Securities** $292,307.69	1	$0.00	0	$0.00		X
ND									
OH									
OK									
OR									
PA		X	**Convertible Securities** $292,307.69	1	$0.00	0	$0.00		X
RI									
SC									
SD									
TN		X	**Convertible Securities** $292,307.69	1	$0.00	0	$0.00		X
TX		X	**Convertible Securities** $2,923,076.93	10	$0.00	0	$0.00		X
UT									
VT									
VA									
WA									
WV									
WI									
WY									
PR									

* Stem Cell Innovations, Inc. ("Stem Cell") will engage in a merger with Amphioxus Cell Technologies, Inc. ("Amphioxus"), whereby all outstanding shares of Amphioxus capital stock will be converted into the right to receive Stem Cell convertible securities, leaving Stem Cell as the surviving corporation. The following individuals, who are officers, directors and/or affiliates of Amphioxus, will receive the rights to Stem Cell convertible securities as payment for the conversion of their Amphioxus capital stock: James H. Kelly, Mark Germain, Margie Chassman, and David G. Perryman. The rest of the persons who will be given Stem Cell convertible securities as payment for the conversion of their Amphioxus capital stock are not officers, directors, and/or affiliates of Amphioxus.